Company Filing History:
Years Active: 2000-2008
Title: Michel J Tremblay: Innovator in Targeted Pharmaceutical Formulations
Introduction
Michel J Tremblay is a notable inventor based in Neufchatel, Canada. He has made significant contributions to the field of pharmaceuticals, particularly in the development of targeted treatments for infectious diseases. With a total of two patents to his name, Tremblay's work focuses on innovative methods and formulations that enhance the efficacy of medical treatments.
Latest Patents
Tremblay's latest patents include "Methods and formulations for targeting infectious agents bearing host cell proteins." This patent discloses a formulation designed for the treatment of diseases caused by infectious agents that acquire host membrane proteins during their life cycle. The formulation is a targeting pharmaceutical composition that includes a ligand capable of binding to host membrane proteins, coupled with a lipid-comprising vesicle. This vesicle may or may not contain a drug effective in treating the disease. Specific liposomes bearing anti-HLA-DR or anti-CD4 antibodies, which may include antiviral drugs such as anti-HIV medications, are also disclosed and claimed. Additionally, a method of formulation and a method of using this formulation in disease treatment are outlined.
Career Highlights
Tremblay is associated with Infectio Recherche Inc., where he continues to advance his research and development efforts. His work has been instrumental in creating innovative solutions for combating infectious diseases, showcasing his commitment to improving healthcare outcomes.
Collaborations
Some of Tremblay's notable coworkers include Michel G Bergeron and Andre Desormeaux. Their collaborative efforts contribute to the ongoing research and development in the field of infectious disease treatment.
Conclusion
Michel J Tremblay's contributions to targeted pharmaceutical formulations highlight his role as an innovator in the medical field. His patents reflect a dedication to advancing treatment options for infectious diseases, ultimately benefiting public health.